Details der Publikation - Electronic Reporting Systems in Pharmacovigilance: The Implementation of VigiFlow in Brazil

Electronic Reporting Systems in Pharmacovigilance: The Implementation of VigiFlow in Brazil

Abstract Pharmacovigilance is defined by the World Health Organization as the science and practice related to the detection, assessment, understanding and prevention of adverse drug reactions (ADRs). In a well-functioning pharmacovigilance system, information on possible ADRs is collected from patients, health professionals and marketing authorisation holders. Of all data sources for drug safety monitoring, spontaneous reporting systems provide the highest volume of information at the lowest maintenance cost and have proven their value in the early detection of product-related safety issues. At the beginning of 2018, the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária—Anvisa) decided to replace the national electronic reporting system in Brazil (Notivisa) with the system provided by Uppsala Monitoring Centre (VigiFlow) for ADR reporting. This paper describes that process and reports on the progress made by Anvisa in terms of making Brazil compliant with international pharmacovigilance standards as well as significantly increasing the number of individual case safety reports collected..

Medienart:	E-Artikel

Erscheinungsjahr:	2020
Erschienen:	2020

Enthalten in:	Zur Gesamtaufnahme - volume:34
Enthalten in:	Pharmaceutical medicine - 34(2020), 5 vom: 15. Sept., Seite 327-334

Sprache:	Englisch

Beteiligte Personen:	Vogler, Marcelo [VerfasserIn] Ricci Conesa, Heloísa [VerfasserIn] de Araújo Ferreira, Karla [VerfasserIn] Moreira Cruz, Flávia [VerfasserIn] Simioni Gasparotto, Fernanda [VerfasserIn] Fleck, Karen [VerfasserIn] Maciel Rebelo, Fernanda [VerfasserIn] Kollross, Bianca [VerfasserIn] Silveira Gonçalves, Yannie [VerfasserIn]

Links:	Volltext [kostenfrei]

Anmerkungen:	© The Author(s) 2020

doi:	10.1007/s40290-020-00349-6

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2121082972

Internformat


LEADER	01000naa a22002652 4500
001	OLC2121082972
003	DE-627
005	20230504182718.0
007	cr uuu---uuuuu
008	230504s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s40290-020-00349-6 \|2 doi
035			\|a (DE-627)OLC2121082972
035			\|a (DE-He213)s40290-020-00349-6-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
084			\|a PHARM \|q DE-84 \|2 fid
084			\|a 15,3 \|2 ssgn
100	1		\|a Vogler, Marcelo \|e verfasserin \|4 aut
245	1	0	\|a Electronic Reporting Systems in Pharmacovigilance: The Implementation of VigiFlow in Brazil
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s) 2020
520			\|a Abstract Pharmacovigilance is defined by the World Health Organization as the science and practice related to the detection, assessment, understanding and prevention of adverse drug reactions (ADRs). In a well-functioning pharmacovigilance system, information on possible ADRs is collected from patients, health professionals and marketing authorisation holders. Of all data sources for drug safety monitoring, spontaneous reporting systems provide the highest volume of information at the lowest maintenance cost and have proven their value in the early detection of product-related safety issues. At the beginning of 2018, the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária—Anvisa) decided to replace the national electronic reporting system in Brazil (Notivisa) with the system provided by Uppsala Monitoring Centre (VigiFlow) for ADR reporting. This paper describes that process and reports on the progress made by Anvisa in terms of making Brazil compliant with international pharmacovigilance standards as well as significantly increasing the number of individual case safety reports collected.
700	1		\|a Ricci Conesa, Heloísa \|4 aut
700	1		\|a de Araújo Ferreira, Karla \|4 aut
700	1		\|a Moreira Cruz, Flávia \|4 aut
700	1		\|a Simioni Gasparotto, Fernanda \|4 aut
700	1		\|a Fleck, Karen \|4 aut
700	1		\|a Maciel Rebelo, Fernanda \|4 aut
700	1		\|a Kollross, Bianca \|4 aut
700	1		\|a Silveira Gonçalves, Yannie \|4 aut
773	0	8	\|i Enthalten in \|t Pharmaceutical medicine \|d Springer International Publishing, 2008 \|g 34(2020), 5 vom: 15. Sept., Seite 327-334 \|h Online-Ressource \|w (DE-627)56017375X \|w (DE-600)2415180-4 \|w (DE-576)380220989 \|x 1179-1993 \|7 nnns
773	1	8	\|g volume:34 \|g year:2020 \|g number:5 \|g day:15 \|g month:09 \|g pages:327-334
856	4	0	\|u https://dx.doi.org/10.1007/s40290-020-00349-6 \|z kostenfrei \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a FID-PHARM
912			\|a SSG-OPC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_266
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 34 \|j 2020 \|e 5 \|b 15 \|c 09 \|h 327-334

Electronic Reporting Systems in Pharmacovigilance: The Implementation of VigiFlow in Brazil

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände